Conference Coverage

VIDEO: Dr. Hope S. Rugo discusses immunotherapy, neoadjuvant treatment highlights


 

AT SABCS 2015

References

SAN ANTONIO – Dr. Hope S. Rugo shared her insights on breast cancer research presented at the San Antonio Breast Cancer Symposium, focusing particularly on neoadjuvant treatments and immunotherapy.

β€œIt’s exciting to think we may be able to treat patients with ER-positive and HER2-negative disease with a relatively limited course of a well-tolerated therapy,” Dr. Rugo said when discussing the results of a phase II trial evaluating neoadjuvant therapy with the antibody-drug conjugate trastuzumab emtansine (T-DM1).

Furthermore, results from another arm within the same trial may help to identify which patients with triple-negative breast cancer can get by with less chemotherapy, and potentially avoid anthracyclines, said Dr. Rugo, professor of medicine at the University of California, San Francisco, in a video interview.

She also untangled the perplexing results from two trials presented evaluating neoadjuvant carboplatin, and discussed the highlights of immunotherapy research presented at the symposium.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

lnikolaides@frontlinemedcom.com

Recommended Reading

Does the Mediterranean diet reduce the risk of breast cancer?
MDedge ObGyn
Early infection-related hospitalization portends poor breast cancer prognosis
MDedge ObGyn
Premenopausal women with luminal A tumors may be able to skip chemo
MDedge ObGyn
VIDEO: Cleveland Clinic experts provide SABCS take-home messages
MDedge ObGyn
Cancer incidence higher in men, blacks
MDedge ObGyn
Neratinib shows consistent breast cancer benefit at 3 years
MDedge ObGyn
ESR1 mutations linked with poorer survival from ER-positive breast cancer
MDedge ObGyn
T-DM1 trial points way to de-escalation of breast cancer therapy
MDedge ObGyn
Ovarian suppression during breast cancer chemotherapy helped preserve long-term function
MDedge ObGyn
VIDEO: Dr. William Gradishar says tools to define patients for targeted therapy are on the horizon
MDedge ObGyn